Combination therapy with anti-PD-L1 and compound 968 results in increased secretion of granzyme B, CXCL10, and CXCL11 by CD4 + and CD8 + T cells, thereby bolstering CD3 + T cell infiltration into tumor microenvironments [202]. The gene discussed is CD8A; the disease is neoplasm.